KRISTINE:T-DM1联合帕妥珠单抗对比化疗联合曲妥珠单抗和帕妥珠单抗新辅助治疗HER2阳性乳腺癌的3期随机试验
KRISTINE是一项在68个中心开展的随机、开放标签3期试验,共纳入444例HER2阳性II-III期可手术乳腺癌患者,比较T-DM1联合帕妥珠单抗与多西他赛、卡铂联合曲妥珠单抗和帕妥珠单抗的新辅助疗效。
要点
- T-DM1联合帕妥珠单抗的3-4级不良事件(13% vs 64%)和严重不良事件(5% vs 29%)更少。
- 化疗联合双HER2阻断仍是病理完全缓解率更高的新辅助选择。
核心结论
- 传统新辅助化疗联合双HER2阻断(多西他赛、卡铂联合曲妥珠单抗和帕妥珠单抗)比T-DM1联合帕妥珠单抗使显著更多患者达到病理完全缓解。
- T-DM1联合帕妥珠单抗组的3-4级和严重不良事件在数值上更少。
- 需要进一步努力在不增加毒性的情况下提高化疗疗效。
研究设计与样本
- 随机、开放标签、多中心3期KRISTINE试验,在亚洲、欧洲、美国、加拿大的68个Translational Research In Oncology中心开展。
- 纳入18岁及以上、中心确认HER2阳性II-III期可手术乳腺癌(肿瘤>2 cm)、ECOG 0-1、基线LVEF至少55%的患者。
- 2014年6月25日至2015年6月15日随机分配444例患者:T-DM1联合帕妥珠单抗组223例,多西他赛、卡铂联合曲妥珠单抗和帕妥珠单抗组221例。
- 按1:1随机,区组大小4,按激素受体状态、诊断时分期和地理区域分层。
- 主要终点为意向治疗人群中病理完全缓解(ypT0/is, ypN0)的患者数,基于局部评估。
主要发现
- 新辅助治疗期间,T-DM1联合帕妥珠单抗组3-4级不良事件29例(13%,223例中)vs 化疗联合双靶向组141例(64%,219例中)。
- 严重不良事件11例(5%,223例中)vs 63例(29%,219例中)。
- T-DM1联合帕妥珠单抗组最常见3-4级不良事件:血小板减少3例(1%)vs 11例(5%)、乏力3例(1%)vs 7例(3%)、丙氨酸氨基转移酶升高3例(1%)vs 4例(2%)、低钾血症3例(1%)vs 5例(2%)。
关键数值与推荐
- 多西他赛、卡铂联合曲妥珠单抗和帕妥珠单抗方案:多西他赛75 mg/m2;卡铂AUC 6 mg/mL×min;曲妥珠单抗8 mg/kg负荷剂量,6 mg/kg维持剂量;帕妥珠单抗剂量同前,每3周一次,共6周期。
- 所有治疗均静脉给药。
- 病理完全缓解定义为ypT0/is, ypN0,基于新辅助治疗完成后14天至6周内乳腺癌手术标本的局部评估。
临床怎么用
- 对于HER2阳性II-III期可手术乳腺癌,新辅助化疗联合双HER2阻断(多西他赛、卡铂联合曲妥珠单抗和帕妥珠单抗)的病理完全缓解率更高。
- T-DM1联合帕妥珠单抗可作为毒性更低的候选方案,但病理完全缓解率较低。
- 临床决策需权衡病理完全缓解率与毒性负担,并考虑后续辅助治疗策略。
- 该试验随访仍在进行,辅助阶段数据待报告。
局限性
- 主要终点病理完全缓解基于局部评估,非中心评估。
- 随访仍在进行,无长期生存数据。
- 试验由F Hoffmann-La Roche和Genentech资助。
- 开放标签设计可能影响不良事件报告。
- 未报告生物标志物或亚组分析数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. METHODS: We did a randomised, open-label phase 3 KRISTINE trial in 68 Translational Research In Oncology centres (hospitals and specialty cancer centres in Asia, Europe, USA, and Canada). Eligible participants were aged 18 years or older with centrally confirmed HER2-positive stage II-III operable breast cancer (>2 cm tumour size), an Eastern Cooperative Oncology Group performance status of 0-1, and a baseline left ventricular ejection fraction of at least 55% (by echocardiogram or multiple-gated acquisition scan). We randomly assigned participants (1:1) to receive either trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab. We did the randomisation via an interactive response system under a permuted block randomisation scheme (block size of four), stratified by hormone receptor status, stage at diagnosis, and geographical location. Patients received six cycles (every 3 weeks) of neoadjuvant trastuzumab emtansine plus pertuzumab (trastuzumab emtansine 3·6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m2; carboplatin area under the concentration-time curve 6 mg/mL × min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in the other group]). All treatments were administered intravenously. The primary objective was to compare the number of patients who achieved a pathological complete response (ypT0/is, ypN0), between groups in the intention-to-treat population (two-sided assessment), based on local evaluation of tumour samples taken at breast cancer surgery done between 14 days and 6 weeks after completion of neoadjuvant therapy. Safety was analysed in patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT02131064, and follow-up of the adjuvant phase is ongoing. FINDINGS: Between June 25, 2014, and June 15, 2015, we randomly assigned 444 patients to neoadjuvant treatment with trastuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221). A pathological complete response was achieved by 99 (44·4%) of 223 patients in the trastuzumab emtansine plus pertuzumab group and 123 (55·7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group (absolute difference -11·3 percentage points, 95% CI -20·5 to -2·0; p=0·016). During neoadjuvant treatment, compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer patients receiving trastuzumab emtansine plus pertuzumab had a grade 3-4 adverse event (29 [13%] of 223 vs 141 [64%] of 219) or a serious adverse event (11 [5%] of 223 vs 63 [29%] of 219). The most common grade 3-4 adverse events in the trastuzumab emtansine plus pertuzumab group were decreased platelet count (three [1%] of 223 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (three [1%] vs seven [3%]), alanine aminotransferase increase (three [1%] vs four [2%]), and hypokalaemia (three [1%] vs five [2%]). The most common grade 3-4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group were neutropenia (55 [25%] of 219 vs one [<1%] of 223 with trastuzumab emtansine plus pertuzumab), diarrhoea (33 [15%] vs 2 [<1%]), and febrile neutropenia (33 [15%] vs 0). No deaths were reported during neoadjuvant treatment. INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Further efforts to improve the efficacy of chemotherapy without imparting more toxicity are warranted. FUNDING: F Hoffmann-La Roche and Genentech.
引用
- Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2017. PMID: 29175149. doi:10.1016/S1470-2045(17)30716-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。